Dr Buch. ORAL Surveillance. MACE, VTE, Malignancy all more common in those with high (>20%) baseline CV risk or history CAD. HRs 1-2 for most but for VTE and high baseline CV risk, HR 6-11! @RheumNow #EULAR2022 POS0237 https://t.co/9DI4KotyOp